Table II.
Univariate Survival Analysis in 149 Black Patients with Mycosis Fungoides / Sézary syndrome
| Clinical Characteristic | N | Overall Survival (OS) from presentation | Disease Specific Survival (DSS) from presentation | ||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age at diagnosis (per year) | 149 | 1.024 (1.002–1.046) | .033 | 1.003 (0.975–1.032) | 0.846 |
| Sex | 149 | ||||
| Female | 1.0 | 1.0 | |||
| Male | 0.614 (0.311–1.215) | .161 | 0.864 (0.333–2.245) | 0.764 | |
| Diagnosis Delay (per year) | 133 | 0.978 (0.922–1.037) | .448 | 0.991 (0.919–1.067) | 0.803 |
| Referral Delay (per month) | 144 | 1.0 (0.999–1.0) | .408 | 1.0 (0.999–1.0) | 0.376 |
| Birth place | 91 | ||||
| US | 1.0 | 1.0 | |||
| Non-US | 1.77 (0.803–3.904) | .157 | 1.437 (0.485–4.259) | 0.513 | |
| Healthcare coverage | 142 | ||||
| Private/HMO | 1.0 | 1.0 | |||
| Medicaid | 1.044 (0.409–2.668) | .928 | 1.28 (0.444–3.667) | .65 | |
| Medicare | 0.971 (0.413–2.284) | .947 | 0.186 (0.024–1.442) | .108 | |
| Median household Income* | 140 | ||||
| 38K or less | 1.0 | 1.0 | |||
| $38–47K | 0.588 (0.201–1.721) | .332 | 0.702 (0.168–2.939) | 0.628 | |
| $48–63K | 0.823 (0.298–2.271) | .707 | 1.095 (0.292–4.102) | 0.893 | |
| $64K or more | 0.794 (0.336–1.875) | .599 | 0.844 (0.256–2.778) | 0.78 | |
| Skin lesions | |||||
| Patches | 149 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 0.131 (0.065–0.263) | <.001 | 0.172 (0.068–0.439) | <.001 | |
| Plaques | 149 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 2.058 (1.027–4.126) | .042 | 2.6 (0.971–6.961) | 0.057 | |
| Tumors and nodules | 149 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 7.634 (3.209–18.162) | <.001 | 10.35 (3.499–30.612) | <0.001 | |
| Erythroderma | 149 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 6.04 (2.521–14.467) | <.001 | 6.001 (1.878–19.17) | 0.002 | |
| Folliculotropic | 149 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 2.411 (0.852–6.826) | .097 | 3.336 (0.981–11.346) | 0.054 | |
| Hyperpigmented lesions | 145 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 1.289 (0.617–2.693) | .5 | 1.318 (0.486–3.57) | 0.587 | |
| Hypopigmented lesions | 145 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 0.044 (0.006–0.32) | .002 | - | - | |
| Clinical Stage | 149 | ||||
| IA | 1.0 | 1.0 | |||
| IB | 0.79 (0.22–2.831) | .717 | 0.533 (0.033–8.624) | .658 | |
| IIA | 4.405 (1.222–15.882) | .023 | 12.195 (1.331–111.718) | .027 | |
| IIB | 11.106 (3.033–40.664) | <.001 | 35.857 (3.912–328.689) | .002 | |
| IIIA / IIIB | -- | -- | -- | -- | |
| IVA / IVB | 8.939 (2.779–28.758) | <.001 | 19.202 (2.235–164.974) | .007 | |
| Early/Late stage disease | 149 | ||||
| Early stage (IA-IIA) | 0.1 | 1.0 | |||
| Late stage (IIB-IVB) | 6.838 (3.385–13.811) | <.001 | 11.365 (4.077–31.68) | <.001 | |
| T stage | 149 | ||||
| T1 | 1.0 | 1.0 | |||
| T2 | 1.568 (0.509–4.828) | .433 | 2.692 (0.319–22.696) | .363 | |
| T3 | 12.043 (3.355–43.231) | <.001 | 32.933 (3.591–302.049) | .002 | |
| T4 | 5.825 (1.707–19.877) | .005 | 14.353 (1.617–127.425) | .017 | |
| N stage | 149 | ||||
| N0 | 1.0 | -- | 1.0 | ||
| N1/2 | 5.362 (2.228–12.906) | <.001 | 9.682 (2.378–39.417) | .002 | |
| Nx | 11.506 (4.43–29.879) | <.001 | 40.566 (10.152–162.101) | <.001 | |
| N3 | 9.269 (2.918–29.443) | <.001 | 19.186 (3.157–116.613) | .001 | |
| M stage | 149 | ||||
| M0 | 1.0 | 1.0 | |||
| M1 | 3.979 (0.94–16.841) | .061 | 7.567 (1.7–33.683) | .008 | |
| B stage | 149 | ||||
| B0 | 1.0 | 1.0 | |||
| B1 | 7.298 (2.127–25.043) | .002 | - | - | |
| B2 | 5.196 (2.371–11.388) | <.001 | 5.755 (2.132–15.531) | .001 | |
| Blood work | |||||
| WBC | 134 | ||||
| Normal | 1.0 | 1.0 | |||
| Elevated | 4.564 (1.754–11.878) | .002 | 5.224 (1.579–17.285) | .007 | |
| Lymphocytes Count | 134 | ||||
| Normal | 1.0 | 1.0 | |||
| Elevated | 5.156 (1.135–23.419) | .034 | 3.69 (0.453–30.046) | .222 | |
| Eosinophils Count | 133 | ||||
| Normal | 1.0 | 1.0 | |||
| Elevated | 1.93 (0.662–5.627) | .229 | 3.894 (1.241–12.217) | .02 | |
| LDH | 122 | ||||
| Normal | 1.0 | 1.0 | |||
| Elevated | 7.085 (2.662–18.855) | <.001 | 5.49 (1.782–16.918) | .003 | |
Abbreviations: US, United States; HMO, health maintenance organization; WBC, white blood count; LDH, lactate dehydrogenase
*
Median household income national quartile for patient residential ZIP code